Form 4: Vera Therapeutics Director Acquires 14,000 Stock Options
SEC Filing
Patrick G. Enright, a director of Vera Therapeutics, acquired 14,000 stock options on May 15, 2024, according to a recent SEC filing.
Summary
- On May 15, 2024, Patrick G. Enright, a director of Vera Therapeutics, acquired 14,000 stock options.
- The exercise price of these options is $42.69.
- The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, contingent upon continuous service.
- The options also vest fully upon a change in control, subject to continuous service through that date.
- The expiration date for these options is May 14, 2034.
- Following the transaction, Enright directly owns 14,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reflecting a standard transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the holdings and transactions of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction: Patrick G. Enright acquired 14,000 stock options. |
| 05/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.